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validated (n = 145) prospectively with disease-free sur-
vival (DFS) at the 10-year follow-up. DFS was signifi-
cantly different between the PMR  ≤ 12 versus the PMR > 
12 group with a hazard ratio (HR) of 2.74 (p < 0.001) in 
the validation cohort and also for the patient subgroup 
treated additionally with endocrine therapy (HR 2.47; p = 
0.001).  Conclusions: Early-stage lymph node-positive 
breast cancer patients with low  PITX2 methylation do 
benefit from adjuvant anthracycline-based chemother-
apy. Patients with a high  PITX2 DNA methylation ratio, 
approximately 30%, show poor outcome and should 
thus be considered for alternative chemotherapy regi-
mens. 
 © 2018 The Author(s). Published by S. Karger GmbH, Freiburg 
 Introduction 
 Anthracycline-based chemotherapy has proven efficacy as adju-
vant treatment in early breast cancer patients with lymph node-
positive disease  [1] . However, controversial discussions have 
emerged about the possibility of long-term anthracycline-related 
toxic effects, particularly cardiotoxicity like congestive cardiac fail-
ure and the risk of acute myeloid leukemia or myelodysplastic syn-
 Keywords 
 PITX2 DNA methylation · Therapy prediction · Breast 
cancer 
 Summary 
 Background: Breast cancer patients at high risk for recur-
rence are treated with anthracycline-based chemother-
apy, but not all patients do equally benefit from such a 
regimen. To further improve therapy decision-making, 
biomarkers predicting outcome are of high unmet medi-
cal need.  Methods: The percent DNA methylation ratio 
(PMR) of the promoter gene coding for the Paired-like 
homeodomain transcription factor 2 (PITX2) was deter-
mined by a validated methylation-specific real-time poly-
merase chain reaction (PCR) test. The multicenter study 
was conducted in routinely collected archived formalin-
fixed paraffin-embedded (FFPE) tissue from 205 lymph 
node-positive breast cancer patients treated with adju-
vant anthracycline-based chemotherapy.  Results: The 
cut-off for the  PITX2 methylation status (PMR = 12) was 
confirmed in a randomly selected cohort (n = 60) and 
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drome  [2] . According to current national and international guide-
lines, standard of care are anthracyclines followed by taxanes. Also 
taxanes have significant toxic side effects, especially polyneuropa-
thy. It has been shown that anthracycline-free regimens are not in-
ferior to anthracyclines  [3] . The question arises whether patients 
require both chemotherapy components and whether some pa-
tients might be sufficiently treated with anthracycline or taxanes 
alone. Subsequently, a significant number of breast cancer patients 
could be spared to experience such severe secondary diseases if 
predictive tests were available to identify patients with good out-
come after anthracycline-based chemotherapy or taxane alone and 
thus would support the treating physicians to apply such therapy. 
Such a fundamental improvement of adjuvant chemotherapy selec-
tion would require predictive tests for both anthracyclines and 
taxanes.
 Paired-like homeodomain transcription factor 2 (PITX2) func-
tions in the Wnt signaling pathway by recruiting and stabilizing 
cytosolic β-catenin, which triggers transcription of cell cycle-regu-
latory and proliferation genes (e.g. those coding for cyclin D1 and 
c-Myc) and subsequently enhances cell proliferation  [4] . Methyla-
tion of the  PITX2 gene promoter leads to epigenetic silencing of 
this transcription factor and subsequent changes in molecular sign-
aling. DNA methylation plays a crucial role in the development 
and progression of a variety of cancers, including breast cancer 
 [5–9] .
 Significant evidence has accumulated that methylation of the 
 PITX2 gene promoter might serve as a predictive and prognostic 
biomarker in a variety of cancers, including high-risk breast cancer 
patients  [10–14] .
 Hayes  [15] meticulously defined the criteria for biomarker tests 
in order to qualify for clinical use: demonstration of analytical va-
lidity, proven clinical/biological validity and clinical utility. The 
present study describes the clinical utility of a  PITX2 DNA meth-
ylation assay targeting the P2 promoter of the gene. This assay has 
been developed as an accurate, reproducible and reliable quantita-
tive methylation-specific polymerase chain reaction (PCR) assay 
utilizing genomic DNA extracted from routinely available forma-
lin-fixed primary breast cancer tumor tissue, thus fulfilling the re-
quirements for analytical validity. Different methods of determin-
ing the  PITX2 percent DNA methylation ratio (PMR) by microar-
ray testing or PCR-based quantification resulted in comparable 
statistically significant PMR values to predict a patient’s outcome 
while receiving adjuvant anthracycline containing therapy  [10, 14] . 
However, these assays were all research tests, not analytically vali-
dated and therefore do not qualify according to Hayes  [15] as suit-
able for the clinical routine setting. The present study aimed at 
validating the  PITX2 DNA methylation status by applying a fully 
analytically validated assay  [16] in a prospective, predefined analy-
sis to predict outcome in lymph node-positive breast cancer pa-
tients receiving adjuvant anthracycline-based chemotherapy. The 
results show that the  PITX2 DNA methylation assay can be used to 
further improve the concept of individualized cancer therapy deci-
sion-making and can support physicians on a case-by-case basis to 
optimize the treatment plan for each single breast cancer patient.
 Material and Methods 
 Patients, Samples, Study Design and Conduct 
 From 316 patients enrolled in this study who underwent surgery between 
1987 and 2011, 205 patients were suitable for the final analyses with the follow-
ing clinical and technical eligibility criteria: histologically confirmed invasive 
breast cancer, primary tumor stage pT1, pT2 or pT3, histologically confirmed 
lymph node involvement ( ≥ N1), estrogen receptor(ER)-positive (progesterone 
positivity alone was not eligible), human epidermal growth factor receptor 2 
(HER2)-negative (triple-negative breast cancers were excluded), standard-of-
care adjuvant anthracycline-based chemotherapy (none of the patients received 
neoadjuvant treatment), no dose-dense therapy, no other primary systemic 
chemotherapy except for endocrine therapy, no additional taxanes, availability 
of clinical follow-up data for at least 18 months, valid  PITX2 PMR values per 
tissue sample assessed. The Consolidated Standards of Reporting Trials (CON-
SORT) diagram ( fig. 1 ) lists all patients assessed for eligibility and the reasons 
for exclusion.
 Surgical specimens from primary tumors (formalin-fixed paraffin-embed-
ded (FFPE) tissue) and corresponding clinical data were obtained from the fol-
lowing 3 institutes: Klinikum rechts der Isar of the Technical University of Mu-
nich (TUM), Munich, Germany; Erasmus University Medical Center, Rotter-
dam, The Netherlands; Martin-Luther-University Halle, Halle (Saale), Ger-
many. For all patients, source data verification was performed. Any experiments 
on humans cited were conducted in accordance with the Declaration of Hel-
sinki (1964). Ethical committee approval or appropriate consent according to 
national law and institutional requirements are archived at each site.
 A sample size of at least 65 events for the validation set study group was 
calculated based on available clinical data and a hazard ratio (HR) of 2.0 with a 
statistical significance level of α = 5% and a power of 80%. Based on these as-
sumptions, a sample size of 145 patients (validation set study group) for the 
clinical validation study was determined. Therefore, out of the 205 patients, a 
training set of 60 patients was randomly selected (assuring the same percentage 
of patients experiencing an event and treatment with endocrine therapy) and 
used for determining the optimal  PITX2 PMR cut-off value (training set cut-off 
study group). After confirmation of the clinical cut-off with the training set cut-
off study group, the clinical validation study protocol with the predefined ob-
jectives of the study was locked. All procedures and above parameters for the 
prospective analysis were conducted as predefined in the study protocol. The 
characteristics of the patient populations are described in  table 1 .
 PITX2 DNA Methylation Assay 
 All primary FFPE breast cancer tissue samples were coded to ensure blind-
 Fig. 1. CONSORT diagram. The diagram depicts the eligibility of patients and 
the respective samples that were included in the clinical validation study and 
the reasons for non-inclusion. 
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 Table 1.  Patient study groups and their characteristics
Classification Training set cut-off 
study group
Validation set study 
group
Clinical analysis study 
 group
n = 60 % n = 145 % n = 205 %
Age, years
<50 31 51.7 57 39.3 88 42.9
≥50 29 48.3 88 60.7 117 57.1
T stage
T1 24 40.0 75 51.7 99 48.3
T2, T3, T4, Tx 36 60.0 70 48.3 106 51.7
N stage
N1 45 75.0 110 75.9 155 75.6
N2 13 21.7 34 23.4 47 22.9
N3 2 3.3 1 0.7 3 1.5
Grading G
G1 0 0.0 9 6.2 9 4.4
G2 38 63.3 100 69.0 138 67.3
G3 22 36.7 36 24.8 58 28.3
Lymph nodes involved, n
1‒3 37 61.7 94 64.8 131 63.9
>3 23 38.3 51 35.2 74 36.1
ER positivity 60 100 145 100 205 100
HER2 negativity 60 100 145 100 205 100
Endocrine therapy
Yes 4 1 68.3 99 68.3 140 68.3
No 19 31.7 46 31.7 65 31.7
Disease recurrence
Yes 31 51.7 74 51.0 105 51.2
No 29 48.3 71 49.0 100 48.8
Disease recurrence (plus ET)
Yes 18 30.0 43 29.7 61 29.8
No 23 38.3 56 38.6 79 38.5
Overall survival
Yes 23 38.3 50 34.5 73 35.6
No 37 61.7 95 65.5 132 64.4
Radiotherapy
Yes 42 70.0 106 73.1 148 72.2
No 18 30.0 39 26.9 57 27.8
PMR (cut-off)
≤12 41 68.3 102 70.3 143 69.8
>12 19 31.7 43 29.7 62 30.2
ER = Estrogen receptor, HER2 = human epidermal growth factor receptor 2, ET = endocrine therapy, PMR = per-
cent DNA methylation ratio.
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ing of the operator while conducting the  PITX2 DNA methylation assay. The 
 PITX2 test (QIAGEN therascreen ®  PITX2 RGQ PCR kit) is a quantitative 
methylation-specific real-time PCR test (qMSP), intended for the determina-
tion of the PMR in the promotor 2 (P2) of the  PITX2 gene in primary FFPE 
breast cancer tissue  [11] . Genomic DNA (gDNA) was extracted and purified 
from FFPE primary tumor tissue using the QIAamp DSP DNA FFPE Tissue Kit 
(QIAGEN, Hilden, Germany). After bisulfite conversion with the Epitect Fast 
DNA Bisulfite Kit (QIAGEN, Hilden, Germany), the PMR of 3 CpG motifs of 
the  PITX2 gene P2  [11] was quantified by qMSP using the therascreen  PITX2 
RGQ PCR kit, containing the quantitative PCR (qPCR) reaction mix, primer 
and probes as well as positive and negative controls. The assay was performed 
on the Rotor-Gene Q MDx real-time PCR platform (QIAGEN, Hilden, Ger-
many) and automatically assessed by the Rotor-Gene AssayManager ® software 
V2.1 with installed Gamma Plug-in and  PITX2 -specific assay profile (thera-
screen_PITX2_FFPE_CE Assay Profile v1.0) for data analysis and quality con-
trol  [16] .
 Statistical Methods 
 Disease-free survival (DFS) was the primary endpoint and defined as the 
time from primary surgery to the first documented DFS event. The date of pri-
mary surgery is considered as the follow-up index date. DFS events include re-
appearance of the cancer disease (local disease recurrence or distant metastasis), 
secondary malignancies considered life-threatening, and death of any cause. 
Secondary malignancy was observed in 6 cases: 2 patients with gastric cancer 
and 1 patient with acute lymphatic leukemia; these occurrences were classified 
as DFS events. 2 patients had malignancies with excellent prognosis, 1 of the 
corpus uteri and 1 of the bladder, and were not considered life-threatening can-
cers and therefore not classified as DFS events. 1 patient who died from colon 
cancer without recurrence of breast cancer was classified as death of any cause.
 The  PITX2 cut-off value for DFS was established with the ‘maximum-se-
lected log-rank statistic’ using the maxstat.test function as implemented by the 
program library ‘maxstat’ of the program ‘R’ (R Development Core Team 2012) 
 [17] . For patients (n = 15) who died without recurrence of cancer, competing 
risks analysis according to Fine and Gray  [18] was applied. Analysis was per-
formed for DFS follow-up time censored at 10 years. Survival curves were calcu-
lated according to the incidence function  [18] . The primary objective was to 
confirm the predictive value of  PITX2 DNA methylation applying the pre-de-
fined cut-off value of PMR = 12 as stated in  figure 1 in FFPE primary breast 
cancer tumor tissue samples in an independent patient cohort (n = 145). The 
study was considered successful if a statistically significant differentiation in the 
primary endpoint DFS was observed between patients with PMR  ≤ 12 versus 
those with a PMR > 12. The log-rank test was used for calculating the respective 
p-values and a 2-sided significance level of 5% was considered significant. R soft-
ware version: 3.4.1 (2017–06–30) – ‘Single Candle’, The R Foundation for Statis-
tical Computing, 2017. The relationship between  PITX2 DNA methylation and 
established clinical factors with the primary endpoint DFS was analyzed using 
univariate and multivariate Cox proportional hazard models  [19, 20] .
 Results 
 Patient Characteristics and Study Populations 
 Patient study groups and their characteristics are presented in 
 table 1 . All patients had received anthracycline-based chemother-
apy consisting of epirubicin in combination with cyclophospha-
mide and fluorouracil or cyclophosphamide alone. Current na-
tional and international guidelines recommend anthracycline-tax-
ane combination regiments. Patients treated with taxanes were not 
included in the present study because the primary goal was to vali-
date the value of  PITX2 DNA methylation to predict the outcome 
of patients receiving anthracyclines.
 Noteworthy, the majority (68.3%) but not all patients (because 
the threshold of ER positivity changed during the enrollment pe-
riod, >10% down to >1% stained tumor cells in order to qualify for 
ER positivity) received endocrine therapy (according to guidelines) 
in addition to chemotherapy. 15 patients died without experiencing 
disease recurrence, which prompted us to analyze the predictive 
value not only with Kaplan-Meier analysis but also with competing 
risks methodology  [18] . The patient cohort (n = 205) was divided 
into a ‘training set cut-off study group’ (n = 60) and a ‘validation set 
study group’ (n = 145). The total patient cohort (‘clinical analysis 
study group’; n = 205) was used for additional clinical analyses.
 PITX2 PMR Cut-off Confirmation 
 To determine a PMR cut-off that identifies patients with good 
and poor outcome, i.e. short and long DFS, original microarray data 
of a previous breast cancer study  [10] were mathematically con-
verted into PMR values.  PITX2 DNA methylation determined by 
the PCR-based therascreen  PITX2 RGQ PCR kit in 121 fresh-frozen 
tissue samples of that same study served as transformation curve to 
convert all data (n = 204) of that study  [10] into PMR values. Ap-
plying log-rank statistics, a  PITX2 cut-off value of PMR 12 was es-
 Fig. 2. Cut-off determination and Schoenfeld plot.  a Statistical determination 
of  PITX2 DNA PMR cut-off points (n = 60); training set; competing risks anal-
ysis, 5-year time of follow-up. PMR data were determined with the thera-
screen ®  PITX2 RGQ PCR kit. y-Axis: standardized log-rank statistics; x-axis: 
PMR. The dashed vertical line marks the maximum log-rank statistic at a 
 PITX2 PMR cut-off point of 12.  b Schoenfeld residues plot of  PITX2 PMR with 
respect to disease-free survival (10-year time of follow-up). Dashed line: hazard 
ratio (HR) of 1.0; solid line: HR applying the cut-off value of PMR 12 at a given 
time. The gray area represents the standard error. 
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tablished (unpublished data). However, the previous studies used 
fresh-frozen tissue, and although Harbeck et al.  [13] have demon-
strated an excellent correlation for the  PITX2 DNA methylation 
status analyzed by qPCR in fresh-frozen and FFPE tissue, we also 
reconfirmed, in a cohort of 60 breast cancer patients randomly se-
lected from the clinical analysis study group (n = 205), the cut-off 
value in FFPE tissue (training set cut-off study group, patients 
treated with anthracycline-based chemotherapy including 41 pa-
tients treated additionally with endocrine therapy) ( table  1 ). In 
these 60 patients, using gDNA extracted from primary breast can-
cer tumor FFPE tissue, the cut-off value of PMR = 12 was con-
firmed by log-rank statistics when tested over a PMR range from 0 
 Fig. 3. Survival analysis. The high-risk breast cancer patient groups were subjected to competing risks analysis and Kaplan-Meier survival analysis with a follow-
up time of 10 years.  a Clinical validation set study group (n = 145); patients treated with anthracycline-based chemotherapy with and without endocrine therapy, 
competing risks analysis.  b Clinical validation set study group (n = 145); patients treated with anthracycline-based chemotherapy with and without endocrine 
therapy, Kaplan-Meier analysis.  c Clinical analysis study group (n = 205); patients treated with anthracycline-based chemotherapy with and without endocrine 
therapy, competing risks analysis.  d Clinical analysis study group (n = 205), patients treated with anthracycline-based chemotherapy with and without endocrine 
therapy, Kaplan-Meier analysis.  e Clinical analysis study group (n = 65); patients treated with anthracycline-based chemotherapy only, Kaplan-Meier analysis. 
 f Clinical analysis study group (n = 140); patients treated with anthracycline-based chemotherapy plus endocrine therapy, Kaplan-Meier analysis. 
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to 50 ( fig. 2 a). Furthermore, applying the chi-squared test for the 
proportional hazards regression model (Schoenfeld residues plot; 
 fig. 2 b), the effect of the  PITX2 DNA methylation cut-off at PMR 12 
remained stable over the period of 10 years of follow-up time  [21] .
 Clinical Validation Study 
 The clinical validation study (n = 145; validation set study 
group) was conducted under an approved study protocol with a 
predefined endpoint and a predetermined  PITX2 DNA methyla-
tion PMR cut-off value of 12. The results demonstrate that patients 
with a PMR  ≤ 12 (70.3% of patients) ( table 1 ) do benefit from an-
thracycline-based chemotherapy while patients with PMR > 12 
(29.7% of patients) ( table  1 ) have a lower probability to benefit 
from this kind of chemotherapy ( fig. 3 ).
 In the validation set study group, 10 patients died (cause of 
death unknown) without experiencing recurrence from breast can-
cer. Survival analysis applying Kaplan-Meier analysis censors pa-
tients in case of death, implying these patients have the same risk as 
compared to the overall study patient population. In the situation 
where patients die without disease recurrence, the problem of com-
peting risks arises. Therefore, we applied the competing risks 
method to reassure the significance of  PITX2 DNA methylation. 
By applying the competing risks method, the PMR = 12 cut-off 
value divided the patients into 2 groups which had an HR for the 
primary endpoint of 1.97, which was statistically significant (p = 
0.016; 95% confidence interval (CI) 1.14–3.43) ( fig.  3 a). Kaplan-
Meier analysis resulted in HR = 2.74, with pronounced statistical 
significance (p < 0.001; 95% CI 1.65–3.54) ( fig. 3 b).
 The clinical analysis study group (n = 205) was also subjected to 
competing risks and Kaplan-Meier analysis applying the cut-off of 
PMR 12. The competing risks analysis resulted in the separation of 
2 patient populations with HR = 1.85 and p = 0.01 (95% CI 1.16–
2.96) ( fig.  3 c) and the Kaplan-Meier analysis showed an even 
higher HR of 2.25 with high statistical significance (95% CI 1.47–
3.44; p < 0.001) ( fig. 3 d). If secondary malignancies were not in-
cluded as events in the statistical analysis, the value of  PITX2 meth-
ylation was also highly statistical significant (n = 205; HR 1.85; p = 
0.010), demonstrating no impact of secondary malignancies. The 
subgroup of patients who received anthracycline-based chemo-
therapy alone, also small in number, demonstrated in Kaplan-
Meier analysis a clear and statistically significant distinction be-
tween 2 groups with an HR of 3.24 (95% CI 1.63–6.42; p < 0.001) 
( fig. 3 e). By focusing on the patient population that has received 
endocrine therapy in addition to anthracycline-based chemother-
apy within the clinical analysis study group, the predictive effect of 
 PITX2 DNA methylation is pronounced; Kaplan-Meier analysis: 
HR = 2.47 with high statistical significance (95% CI 1.41–4.34; p = 
0.001) ( fig. 3 f).
 An important aspect for clinical decision-making is how many 
patients will be diagnosed with a  PITX2 DNA methylation status 
that is close to the cut-off value. We analyzed how many patients 
will be clearly outside of a 20% window at the cut-off value of PMR 
12. In our study, 90.7% of the patients had a PMR below 10 or 
above 14. Only 9.3% had PMR values within this artificial window. 
Therefore, the vast majority of patients will present with an unam-
biguous  PITX2 DNA methylation status.
 Multivariate Analysis 
 In multivariate Cox regression analyses in the validation set 
study group, the  PITX2 DNA methylation status was found to con-
tribute significant information regarding DFS ( table 2 ). The cut-off 
of PMR = 12 demonstrates with an HR of 2.72 (95% CI 1.55–4.78) 
 PITX2 DNA methylation as an independent factor with high statis-
tical significance (p = 0.001) in multivariate analysis. Concerning 
the established prognostic factors, age and lymph node status 
(comparing less than 3 lymph nodes affected vs. more than 3 
lymph nodes) did not contribute any additional information while 
pT stage did, but only if comparing pT1 versus pT2 and not pT1 
versus pT3. The latter might be due to the low number of cases. 
Histological grading was not of statistical significance in the multi-
variate analysis. Besides the  PITX2 DNA methylation status, also 
endocrine therapy contributed statistically significant information.
 Relevance of Tumor Content in FFPE Tissue Sections 
 We observed a significant variation of tumor cell content in the 
tumor tissues assessed. In order to examine the  PITX2 DNA meth-
ylation status dependency on the percentage of tumor cell content, 
the clinical analysis study group (n = 205) was divided into 2 popu-
lations, one with >50–90% tumor content (n = 89) and the other 
one with 5–50% tumor content (n = 116). Kaplan-Meier analysis 
employing the optimal cut-off value of PMR = 12 revealed very 
similar statistics: low tumor content: HR = 2.25 (95% CI 1.22–4.18) 
with a significance level of p = 0.010; high tumor content: HR = 
2.08 (95% CI 1.18–3.66) with a significance of p = 0.012. Therefore, 
the  PITX2 DNA methylation status can be determined by qPCR in 
gDNA extracted from primary breast cancer FFPE tissue inde-
pendent from variation in tumor cell content, and macrodissection 
of tumor samples prior to analysis seems not to be required.
 Table 2.  Multivariate Cox regression analysis to assess the clinical impact 
with respect to DFS of the PITX2 DNA methylation status to predict outcome 
of breast cancer patients after adjuvant anthracycline-based chemotherapy (val-
idation set study group, n = 145)
Variable HR 95% CI p
T stage
T2 vs. T1 2.85 1.52–5.36 0.001
T3 vs. T1 1.55 0.65–3.71 0.324
 Nodal status, LNs > 3 vs. 1–3 1.63 0.90–2.94 0.107
Endocrine therapy, yes vs. no 2.94 1.70–5.09 0.001
Grading, G1/2 vs. G3 1.53 0.88–2.68 0.132
Age, years, >50 vs. ≤50 1.22 0.71–2.09 0.462
PITX2 DNA methylation status, 
PMR ≤ 12 vs. PMR > 12
2.72 1.55–4.78 0.001
DFS = Disease-free survival, HR = hazard ratio, CI = confidence interval, 
LN = lymph node, PMR = percent DNA methylation ratio.
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 Discussion 
 Anthracyclines, typically in combination with taxanes, have 
provided compelling evidence for their efficacy in treating early 
breast cancer patients, both in the adjuvant and neoadjuvant set-
ting  [1] . National and international guidelines recommend anthra-
cycline-based chemotherapy regimens as a most suitable treatment 
option  [22, 23] , despite their considerable associated toxicity even-
tually causing leukemia or congestive heart failure. Unless non-
anthracycline-based chemotherapy improves the outcome similar 
to anthracyclines, they will remain an integral part of adjuvant 
treatment to reduce the risk of disease recurrence as an alternative 
option, if treatment with anthracyclines is insufficient or ineffec-
tive. Predictive cancer biomarkers may help to decide if adjuvant 
systemic anthracycline-based chemotherapy is the right treatment 
option for early breast cancer patients. Our work shows that hypo-
methylation of the  PITX2 gene promoter identifies a subgroup of 
lymph node-positive breast cancer patients treated with anthracy-
cline-based chemotherapy with excellent outcome.
 Several studies have addressed this so far unmet medical need 
for predictive biomarkers; however, none of those approaches have 
transferred into clinical routine. HER2 and topoisomerase IIA 
(TOP2A) have been evaluated for their use as predictive biomark-
ers for anthracycline responsiveness  [24] . The authors came to the 
conclusion that both markers, either alone or in combination, have 
some added value in the prediction of outcome after anthracycline-
based chemotherapy, but their findings do support their use only 
in patients with HER2-amplified or TOP2A-aberrant tumors. Des-
medt et al.  [25] developed an anthracycline-based score, the A-
score, combining TOP2A and signatures of tumor invasion and 
immune response. This A-score demonstrated a high negative pre-
dictive value for anthracycline responsiveness, but additional vali-
dation, especially analytical validity, is missing so far. Commer-
cially available gene signatures such as Endopredict ® (Myriad Ge-
netics Inc., Salt Lake City, UT, USA), OncotypeDX ® (Genomic 
Health, Redwood City, CA, USA), or Mammaprint ® (Agendia 
Inc., Irvine, CA, USA) have not provided evidence to be of merit to 
predict outcome after anthracyclines  [23] . These multigene signa-
tures are highly valuable to define patients who could be spared to 
receive chemotherapy and who are sufficiently treated with endo-
crine therapy alone  [23] .
 The present retrospective study was conducted by applying a 
fully analytically validated quantitative methylation-specific real-
time PCR format  [16] and an optimized clinically validated cut-off 
to extend previously published studies. Hartmann et al.  [10] inves-
tigated the value of  PITX2 DNA methylation in 241 lymph node-
positive, ER-positive and HER2-negative breast cancer patients, a 
patient cohort with the same clinicopathological characteristics as 
the present study, and showed the significant role of  PITX2 DNA 
methylation in the prediction of outcome after adjuvant anthracy-
cline treatment, at that time by applying a microarray-based test. 
Hartmann et al.  [10] used arbitrary quartiles instead of an opti-
mized cut-off, identified through log-rank statistics, to separate hy-
permethylated from hypomethylated tumor specimens, but they 
nevertheless demonstrated that patients with  PITX2 hypermethyl-
ated tumors had a significantly worse outcome than patients with 
hypomethylated tumors. The hypothesis put forward to explain 
this effect is that hypermethylation of  PITX2 results in silencing of 
the Wnt/β-catenin pathway with subsequent downregulation of es-
trogen and its receptor, causing estrogen deprivation/independ-
ency in estrogen-positive cancer cells. The ABCG2 transporter is 
downregulated by estrogen, i.e. estrogen deprivation leads to in-
creased ABCG2 expression. If  PITX2 is hypermethylated, the Wnt/
β-catenin pathway is silenced and subsequent ER downregulation 
leads to overexpression of the ABCG2 transporter and thereby to 
anthracycline resistance  [26, 27] .
 Absmeier et al.  [14] demonstrated the high predictive value of 
 PITX2 DNA methylation for treatment with anthracyclines for tri-
ple-negative breast cancer patients, applying a qPCR-based re-
search test. However, in this study, hypomethylation of  PITX2 was 
associated with poor outcome, instead of hypermethylation as 
demonstrated in the present study and by others  [10, 11, 13] . Tri-
ple-negative breast cancer is a heterogeneous disease, which may 
explain the opposite relationship of  PITX2 DNA methylation. Sub-
types on a molecular level have been proposed to further character-
ize triple-negative breast cancer, and despite some differences in 
the number of subtypes or classifying methods, the clinical rele-
vance of the triple-negative breast cancer subtypes is, however, not 
yet defined. To explain the opposite relationship of  PITX2 DNA 
methylation in triple-negative and ER-positive breast cancer, Au-
bele et al. [12] developed and presented a molecular-pathological 
hypothesis.
 PITX2 DNA methylation not only predicts outcome in high-
risk breast cancer patients treated with anthracycline-based chem-
otherapy, but also predicts outcome in tamoxifen-treated lymph 
node-negative breast cancer patients  [11, 13] . Furthermore,  PITX2 
DNA hypermethylation identifies breast cancer patients who have 
not received any systemic therapy as being at high risk for disease 
recurrence, hinting to the assumption that  PITX2 methylation has 
prognostic value  [28] . So far, there are no data available that dem-
onstrate that  PITX2 DNA methylation can predict outcome after 
taxanes or aromatase inhibitors. The studies available to date sug-
gest that  PITX2 DNA methylation has both prognostic and predic-
tive value. In order to demonstrate that  PITX2 DNA methylation is 
predictive of anthracycline efficacy, additional studies are required 
to investigate the effect in breast cancer patients treated with non-
anthracycline regimens according to current treatment guidelines. 
The proposed study should utilize tissue specimens preferably 
from a randomized trial comparing both treatment modalities and, 
by applying a formal statistical test of the treatment-by-biomarker 
interaction, should be significant as described by Ballmann  [29] .
 Standard of care according to guidelines is anthracycline-based 
chemotherapy. However, it is noteworthy that anthracycline-free 
regimens seem as effective. Shulman et al. [3] demonstrated (Can-
cer and Leukemia Group B (CALGB) 40101 trial) that a single-
agent taxane is not inferior compared to doxorubicin plus cyclo-
phosphamide in ER-positive, HER2-negative disease. In addition, 
in the Oncology Research Trial 9735, Jones et al. [30] even showed 
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that docetaxel with cyclophosphamide is superior to doxorubicin 
and cyclophosphamide.
 The present study represents a multicenter study using routinely 
collected and archived primary tumor tissue samples obtained from 
early-stage high-risk breast cancer patients who have been treated ac-
cording to standard-of-care guidelines. Applying the revised Levels of 
Evidence (LoE) rules for categorization of biomarker studies pub-
lished by Simon et al.  [31] , our applied test and the associated studies 
fulfill the criteria for LoE II. The present study does not meet the cri-
teria for LoE Ib because our tumor samples were not part of a pro-
spectively planned and conducted clinical trial. However, future stud-
ies including a prospective clinical trial in the neoadjuvant setting will 
be conducted to increase the LoE for  PITX2 DNA methylation as a 
clinically useful predictive marker to support the treating physician 
concerning the selection of patients significantly benefiting from ad-
juvant anthracycline-based chemotherapy.
 Among the high-risk breast cancer patients who have been 
treated with endocrine therapy in addition to anthracycline-based 
chemotherapy,  PITX2 DNA methylation identifies a low-risk pa-
tient population (more than 60% of patients in the present study) 
that has a 5-year DFS probability of approximately 88%. Clinical 
trials have demonstrated that lymph node-positive, ER-positive 
and HER2-negative breast cancer patients treated with anthracy-
clines in combination with docetaxel or paclitaxel or paclitaxel in 
combination with gemcitabine showed an approximately 5-year 
DFS probability of 84%  [32] . Therefore, further studies are war-
ranted to support the notion that  PITX2 DNA methylation might 
select patients who are sufficiently treated with anthracycline-
based chemotherapy in combination with endocrine therapy, and 
for whom administration of taxanes can be omitted. This would 
spare patients significant side effects of a chemotherapy compo-
nent that is unnecessary if any benefit is highly unlikely.
 In conclusion, applying a robust, reproducible assay, we can 
now determine the methylation status of the  PITX2 gene in gDNA 
extracted from FFPE primary breast cancer tissue specimens with 
excellent analytical validity. Importantly, patients with a low 
 PITX2 DNA methylation status are sufficiently treated with an-
thracycline-based chemotherapy with or without additional endo-
crine therapy, proven by an extended DFS interval. In contrast, 
patients with high  PITX2 DNA methylation status have a worse 
outcome while on anthracycline-based chemotherapy and should 
be considered for alternative chemotherapy regimens or the addi-
tion of taxanes to the regimen  [22, 23] .
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